An investigation published by the BMJ today raises concern about the motives behind post-marketing studies of new treatments for diabetes and calls for better regulation to ensure "a proper balance" between the commercial and clinical functions of these studies.
Experts warn that these studies are fuelling "catastrophic health expenditure" in low income countries, and a former drug industry employee admits that many of these studies "had more marketing than science behind them."